References
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78. doi: https://doi.org/10.1002/nau.10052
- Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn. 2018;37(3):1152–61. doi: https://doi.org/10.1002/nau.23397
- Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, et al. Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol. 2016;69(2):324–33. doi: https://doi.org/10.1016/j.eururo.2015.07.071
- Tudor KI, Sakakibara R, Panicker JN. Neurogenic lower urinary tract dysfunction: evaluation and management. J Neurol. 2016;263(12):2555–64. doi: https://doi.org/10.1007/s00415-016-8212-2
- Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med. 2013;36(5):402–19. doi: https://doi.org/10.1179/2045772313Y.0000000116
- Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100–19. doi: https://doi.org/10.1016/j.eururo.2008.09.009
- El-Badawi A, Schenk EA. Dual innervation of the mammalian urinary bladder. A histochemical study of the distribution of cholinergic and adrenergic nerves. Am J Anat. 1966;119(3):405–27. doi: https://doi.org/10.1002/aja.1001190305
- Gosling JA, Dixon JS. Sensory nerves in the mammalian urinary tract. An evaluation using light and electron microscopy. J Anat. 1974;117(Pt1):133–44.
- Purves JT, Spruill L, Rovner E, Borisko E, McCants A, Mugo E, et al. A three dimensional nerve map of human bladder trigone. Neurourol Urodyn. 2017;36(4):1015–19. doi: https://doi.org/10.1002/nau.23049
- Roosen A, Wu C, Sui G, Chowdhury RA, Patel PM, Fry CH. Characteristics of spontaneous activity in the bladder trigone. Eur Urol. 2009;56(2):346–53. doi: https://doi.org/10.1016/j.eururo.2008.06.048
- Andersson KE. Bladder activation: afferent mechanisms. Urology 2002;59(5 Suppl 1):43–50. doi: https://doi.org/10.1016/S0090-4295(01)01637-5
- Citeri M, Spinelli M, Zanollo L, Scroppo F, Macrellino E, Redaelli T. Botulinum toxin into the trigone in neurogenic overactive bladder non-responder to detrusor injection. Eur Urol Suppl. 2008;7(3):213. doi: https://doi.org/10.1016/S1569-9056(08)60567-9
- Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–5. doi: https://doi.org/10.1016/j.eururo.2010.02.031
- Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184(6):2423–8. doi: https://doi.org/10.1016/j.juro.2010.08.028
- Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30(7):1242–8.
- Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol. 2012;61(5):928–35. doi: https://doi.org/10.1016/j.eururo.2011.10.043
- Huang M, Chen H, Jiang C, Xie K, Tang P, Ou R, et al. Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J Rehabil Med. 2016;48(8):683–7. doi: https://doi.org/10.2340/16501977-2132
- Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, et al. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord 2016;54(1):46–50. doi: https://doi.org/10.1038/sc.2015.143
- Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol. 2007;177(3):1011–4. doi: https://doi.org/10.1016/j.juro.2006.10.047
- Mascarenhas F, Cocuzza M, Gomes CM, Leão N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn. 2008;27(4):311–4. doi: https://doi.org/10.1002/nau.20515
- Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200. doi: https://doi.org/10.1097/01.ju.0000162035.73977.1c
- Khandelwal C, Kistler C. Diagnosis of urinary incontinence. Am Fam Physician 2013;87(8):543–50.
- Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol Urodyn. 2005;24(1):2–12. doi: https://doi.org/10.1002/nau.20090
- Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–22. doi: https://doi.org/10.1016/S0022-5347(17)42717-0
- Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692–7. doi: https://doi.org/10.1097/00005392-200009010-00018
- Chermansky CJ, Chancellor MB. Use of Botulinum toxin in Urologic diseases. Urology 2016;91:21–32. doi: https://doi.org/10.1016/j.urology.2015.12.049
- Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665. doi: https://doi.org/10.1056/NEJM200003023420918
- Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol. 2006;13(5):3291–5.
- Madersbacher H. Neurogenic bladder dysfunction in patients with myelomeningocele. Curr Opin Urol. 2002;12(6):469–72. doi: https://doi.org/10.1097/00042307-200211000-00004
- Klaphajone J, Kitisomprayoonkul W, Sriplakit S. Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil. 2005;86(11):2114–8. doi: https://doi.org/10.1016/j.apmr.2005.06.008